September 29, 2015 – DelMar Pharmaceuticals Inc.
Abstract to be presented at AACR Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship Conference
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 29, 2015 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that it will present an abstract entitled, “Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain Tumors,” at the American Association for Cancer Research (AACR) Advances in Pediatric Research: From Mechanisms and Models to Treatment and Survivorship conference being held November 9–12, 2015 in Fort Lauderdale, FL.
The Company will present on Tuesday, November 10th during Poster Session A scheduled to begin at 4:30 p.m. The poster presentation will summarize the potential of VAL-083 as a new treatment for malignant pediatric brain tumors in the context of historical clinical trials sponsored by the U.S. National Cancer Institute and DelMar’s recent research.
The Company recently presented an update from its ongoing multicenter Phase I/II clinical study for the treatment of adult refractory glioblastoma multiforme (GBM) at the GBM2015 Conference. VAL-083 demonstrated a favorable safety-profile and doses up to 40mg/m2 were well tolerated by patients receiving three daily doses in a 21 day cycle. A sub-group analysis of patients receiving up to 5 mg/m2 daily x 3 every 21 days (low dose) versus those patients receiving 30mg/m2 or 40mg/m2 (high dose) of VAL-083 demonstrated a dose-related survival benefit in adult GBM patients failing standard front-line therapy and bevacizumab.
VAL-083 is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.
DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory GBM in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA) at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO). As a potential treatment for glioblastoma, VAL-083’s mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes following front-line treatment with Temodar® (temozolomide).
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
For further information, please visit here
DelMar Pharmaceuticals Investor Relations: firstname.lastname@example.org
Phone: (604) 629-5989
Follow us on Twitter @DelMarPharma or
Investor Relations Counsel: Amato & Partners LLC.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
PR Newswire, please visit here